Fig.(4) Schematic illustration of cancer theranostics by the multifunctional NPs hybrid platform. In the interaction between the NPs and the cancer cells, the ligand targeting agent binding to tumor receptor induces internalization and endocytosis of NPs in cancer cells. In diagnosis, the cells are labeled following NPs agent release, which is localized within the cancer cells through various methods. In thermal treatment, the cells are treated with NPs, which are activated by radiation to induce the destruction of cancer cells. In therapy with NPs siRNA delivery, the cells are treated with NPs loaded with siRNA (NPsi oncogenes), which mediate gene silencing and functional effects in mutated cells, to induce effective and cytotoxic destruction of cancer cells. In pharmacotherapy, the therapeutic agent drug release molecule induces the destruction of the cancer cells.